Ingen Will Attend AARC and AzSRC to Exhibit New Products

Management Expands Marketing Tradeshow Programs


YUCAIPA, Calif., June 29, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a medical device manufacturer with an emerging new medical product line targeting the $8B respiratory market, announced today that the company has expanded its tradeshow schedule to include the Arizona Society for Respiratory Care (AzSRC) 44th Annual Conference in August 2010 and the American Association for Respiratory Care (AARC) 56th International Respiratory Conference in December 2010.

The AzSRC conference, which will be held in Phoenix, Arizona, is sponsored by the Arizona Society for Respiratory Care (AzSRC), a non-profit organization that supports and benefits the Respiratory Care Practitioners of Arizona. AzSRC, a chartered affiliate of the American Association for Respiratory Care, was founded to enhance communications and the distribution of information among its members and those interested in Respiratory Care.

The 56th International Respiratory Conference for AARC, which will be held in Las Vegas, Nevada by the American Association for Respiratory Care (AARC) is committed to enhancing the professionalism for respiratory care practitioners, improving their performance on the job, and helping them broaden the scope of knowledge essential to their success. Founded in 1949 with more than 49,000 members nationwide, the AARC is the only professional society for respiratory therapists in hospitals and with home care companies, managers of respiratory and cardiopulmonary services, and educators who provide respiratory care training.

"We continue to reach out to key end markets in order to accelerate our growth in the medical marketplace," said Chairman and CEO Scott R. Sand. "Our intellectual property and proprietary medical products are rapidly gaining recognition in the world markets, while our products continue to see strong domestic demand as well."

http://www.aarc.org/education/meetings/congress/index.cfm

http://www.azsrc.org/conference2010.html

http://www.ingen-tech.com/

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Ingen:

Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements.  While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion.  Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described.  The company's operations and business prospects are always subject to risk and uncertainties.  Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
 



            

Contact Data